Form 4: EyePoint Pharmaceuticals Director Acquires 40,000 Stock Options
SEC Form 4
Director Karen L. Zaderej acquired 40,000 stock options in EyePoint Pharmaceuticals on January 3, 2025.
Summary
- On January 3, 2025, Karen L. Zaderej, a director of EyePoint Pharmaceuticals, acquired 40,000 stock options.
- The options have an exercise price of $8.26.
- The options become exercisable on January 3, 2026, and expire on January 3, 2035.
- Following the transaction, Ms. Zaderej directly owns 40,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock option acquisition by a director.
Industry Context
This is a standard Form 4 filing, reflecting a transaction by a company insider. Option grants are a common form of executive compensation in the pharmaceutical industry.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of transaction: Director acquired stock options |
| 01/03/2026 | Options become exercisable |
| 01/03/2035 | Options expiration date |
| 01/07/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.